Solving problems, restricting orders: Compass on COVID

Diana Kremitske, MS, MHA, MT(ASCP), VP, Diagnostic Medicine Institute, Geisinger, Danville, Pa.: Geisinger has been involved in a regional health collaborative, which is an effort by the commonwealth to support the pandemic response in skilled-nursing facilities. Under our purview are now 229 long-term–care facilities, from skilled-nursing to assisted-living facilities to personal care homes, all of which have different degrees of required medical leadership. That has rallied the team on how we get orders, ensuring results are transmitted in a timely manner, and how authorizations are obtained to do employee testing. Our organization has been involved in many facets of the pandemic response at these facilities, including not only that work and testing but also PPE training and understanding the facility layout.

It’s funded by a grant from the CARES Act that extends from July through December. The commonwealth is speaking to us and other health care facilities involved in the collaborative about the plan for support when the grant awards end.

On supplies we’ve been challenged using a multiplatform strategy to help mitigate these issues. We are using the Hologic Panther for its high-throughput capability and then our supplies changed to about 25 percent of what we had been getting. So we had to work with our surgical teams to see how they could rationalize better pre-procedure testing utilization, carefully considering the rate of positivity observed in the presurgical testing population so we would have the capacity for the nursing homes, other symptomatic testing, and specific requests for surveillance testing in the community.

Darlene Cloutier, how do things stand in western Mass­achusetts?
Darlene Cloutier, MSM, MT(ASCP), HP, director of laboratory operations, Baystate Health, Springfield, Mass.: We have three different platforms running now, one of which is Cepheid for which we are beginning to see an expanded allocation of reagent, which is great. Just this morning we had only 18 tests left in the lab before a shipment arrived, and those 18 remained only because we had backed off rapid testing earlier when we knew we were going to run out.

We have two other platforms: Roche 6800 and Hologic Panther. The most consistent supply chain has been from Roche. We use the Panther to back up our 6800.

In terms of staffing, we’ve done a lot of cross-training. Everyone has been terrific, but burnout is setting in.

Stan Schofield, manufacturers said that if they have to crank up flu tests in manufacturing, they won’t be able to meet both the COVID demand and the flu demand. Can you speak to that?
Stan Schofield, president, NorDx, and senior VP, MaineHealth: We at NorDx are working on a lab-developed flu-COVID assay. All the big manufacturers I’ve talked to are going to a combo multiplex. It will be hard to get single flu, single COVID molecular assays after the next 30 days. We started buying flu Liat kits in June in anticipation of difficulty, and they stopped manufacturing those in early August. The shipment of Liat cartridges that arrived today are a combo, and for 11 hospitals I get 200 cartridges a week.

Everybody is worried about flu. The ambulatory settings are trying to figure out how we’re going to do a flu combo with COVID. We tell them there’s no antigen test that we support that will work that way. We’ve had false-negatives with it. So everything we’re doing as of about November 1 will be an automatic flu-COVID combination. Rarely will you be able to get a single flu. Until we run out of the flu cartridges, we might be able to do it, and when we do the combo LDT we will still have single flu LDT, but it won’t be the high rapid priority that a combo with COVID requires for a patient who’s symptomatic.

As far as instrumentation, we went with open channel and it seems to have been our savior because we’re a low priority state and we’re doing 1,896 tests today. Getting 200 from Roche a day with the 6800 wouldn’t cut it. So our LDT has been our destiny and it’s hard to source, but we’ve stabilized on our supply chain. We’re stockpiling—every conference room and spare cubicle in the administrator area has supplies stacked in it. We’ve been going outside normal channels—buying directly from Europe, from South Korea. But it’s not anywhere near normal ease of use or ease of business. It’s all stressful, it’s all out of the box. But it has served us well.

Clark Day, how are things similar or different at IU Health? And do you have any experience with serology testing?

Clark Day, VP of system laboratory services, Indiana University Health: It is similar for us, but we’re doing fine. We are launching pooling today—our first experience with it. A little trepidation on the pathology side but we’re doing it for our pre-procedural patients only—about 1,800 patients a week.

We too are preparing for flu season with a lot of unknowns. We’re protecting our Roche supply of the PCR-based tests by telling them we want to stay on the single PCR test, not their combo kit. We will launch the combo on Cepheid when it’s available. We also have the Liats regionally in our regional hospitals for combo testing.

We are launching antigen testing, too, on a Sofia platform. We’re going to launch that initially for asymptomatic patients before admission to a double-occupancy room as well as our team members who have incurred a high-risk exposure. We will also test our phlebotomy team members who are going into skilled-nursing facilities, for sequential or repeated testing.

There was a sense of urgency for serology testing in late summer. I was tasked with building as much capacity as possible for it. We were telling Beckman we may need 30,000, 50,000 tests a day. When we launched we struggled to get to five ordered tests a day. Nobody is ordering it. We’re not using it, and it’s off of my radar now.

Has anyone had a different experience with serology testing?
Dr. Lyzak (Alverno): We’ve had interest from a niche area in our organization, behavioral health, where we’ve struggled with how to deal with patients in our EDs who suffer from psychotic breaks. We’ve had patients who are psychotic and COVID positive—a horrible combination of circumstances. We’re going to combine our ID Now capabilities with an IgM assay, which we will have on our Beckman Access in the hospital. If either one of those methods is positive, they’re going to be considered COVID positive. That seems to be the most readily identifiable and somewhat niche indication for that particular test. The IgG otherwise is, as was said, kind of ho-hum—volumes aren’t large. But we may see it pick up with more talk of reinfection.

Rochelle Odenbrett, MT(ASCP), MBA, senior executive director of laboratories, Sanford Health, Sioux Falls, SD: A research branch of our health care organization launched a study using antibody testing on health care workers. We’re testing 3,000 to 4,000 of our front-line staff and we’re redrawing them every 30 to 60 days. So we do get a good number of antibody tests coming into our reference laboratory daily, primarily for that study.

Tylis Chang, what is the current state of play at Northwell?
Tylis Chang, MD, CMIO and vice chair of pathology and laboratory medicine, Northwell Health: We are up to 11 validated different platforms across our core lab and our hospitals. The primary platform is Hologic but we also have Roche and Abbott. The supply chain has been an enormous challenge. We’ve spent a lot of time educating our C-suite about the fact that the PPE supply chain seems to have improved while on our side it’s been the challenge everyone else is experiencing. GenMark has been our most reliable supplier at the hospital level.

We’re using our Abbott ID Nows in a focused way because of the supply chain issue. We’re using them in two major scenarios. The biggest scenario is our partner in the urgent care space for low clinical suspicion cases. We did a correlation. We used Hologic as our primary screening platform and we pooled 20 positives out of our core lab, which we know are primarily asymptomatic outpatient screenings. And we were thrilled to discover that 19 of the 20 correlated. We feared that in that patient population the correlation would be much worse.

We brought serology testing up early when we were uncertain about the supply chain. Seven different assays, none of them lateral flow. We were gratified when we first validated it. The validation I initially did was on employees or patients who were not hospitalized. The clinical sensitivity in PCR-positive validated individuals was blended around 94 percent. Some assays are a little better, some a little worse. But there appears to be a robust five percent who were seronegative.

We went back to revisit the employees who were positive initially, again by a mix of platforms. Not only is there a drop in seropositivity, which we expected, but also there’s a difference among the vendors. What appeared to be good beforehand isn’t now, though the data are preliminary.

John Waugh, do you expect the serology testing to pay off sometime next year as a potential solution to some of the testing dilemmas we face?
John Waugh, MS, MT(ASCP), system VP, pathology and laboratory medicine, Henry Ford Health System, Detroit: You’re asking me to be a fortuneteller. We’re doing a few hundred a day. It’s lackluster in my view. It will take time to see whether that bears fruit or not.

Regarding flu, we’ve asked our clinicians to hold tight on flu testing because we do not have flu in our community now, to avoid burning through flu testing supplies and burning up our staff.

We are expecting antigen testing to come our way in about mid-November. We think it could be helpful for screening populations of people where there are outbreaks—schools, universities, sports teams.

We got our chair of pediatrics to buy off on respiratory syncytial virus testing only for children under age five. We realize there are going to be elderly individuals from time to time, so we will go back to antigen testing for RSV and a PCR test with Cepheid.

Would anyone like to comment on Henry Ford’s approach of discouraging clinicians from ordering flu tests until flu has arrived?
Dr. Fuhrman (OhioHealth): We just struggled with this. We’re working on the combo tests and we have the Liat and Cepheid, which isn’t yet approved. We have no flu in our community, and we decided we needed to give ourselves time to make sure our algorithms were appropriate for symptomatic patients. We normally would turn flu on between September 15 and October 1. We’ve decided we would not even make it available until November at the earliest. We’re going to watch the prevalence of flu in the community as we do that. Our clinical colleagues are okay with this. We have had a few random requests for flu-only testing, which is odd because these patients present with the same symptoms as COVID. So I’ve been challenging our clinicians on the rationale for that.

For inpatients, we are using the BioFire respiratory panel, so we will find flu if there’s flu in the community.

Heather Dawson (Allina): We took out flu antigen testing this year and it’s been an unpopular move. We also made flu PCR difficult to order. We’ve had some supportive ambulatory clinicians who are basically saying, “Please treat empirically, that’s what the guidelines say.” Frankly, it doesn’t matter if it’s flu; you’re going to do COVID and care for the patients. Yes, it matters in certain cases, and where it matters we put those indications in an order and, if you meet the criteria, you can have one. We’ll look at utilization and report back to the group.